| Revenue growth | Q2 revenue +24% YoY, +7% QoQ to ₹1,394 Cr |
|---|---|
| Margins | EBITDA margin 16% vs 13% YoY; Chem Intermediates 11% |
| Demand visibility | Robust opportunity pipeline; 25+ confirmed CDMO molecules |
| Management confidence | Confident of sustaining momentum; FY27 'pivotal year' |
Growth
H1 revenue ₹2,695 Cr (+25%), EBITDA ₹431 Cr (+44%), PAT ₹217 Cr (+50%). Nutrition revenue +50%; Chemical Intermediates EBITDA +226%.
Outlook
Growth expected across all segments in FY27; Multi-Purpose Plant commissioning by year-end; ZettaOne expected 60-70% growth.
Risks
Agrochemicals pressured by China overcapacity; softening B3 feed pricing; higher crude-linked input and utility costs.
Last quarter's promises, checked
Delivered
- H1 EBITDA guided ₹400 Cr+ → ₹431 Cr (= BEAT)
- Sequential rev & EBITDA growth guided → rev ₹1,394 Cr (+7% QoQ), EBITDA ₹221 Cr vs ₹209 Cr (= BEAT)
Investor Presentation filed with BSE, NSE: JUBLINGREA. Summary written with AI assistance from the document.
Jubilant Ingrevia Ltd: key numbers
- Share price
- ₹593.60
- Market cap
- ₹9,455 Cr
- Revenue (annual)
- ₹4,388 Cr
- Net profit (annual)
- ₹277.9 Cr
- P/E (TTM)
- 27.0×Sector 34.1×
- Promoter holding
- 45.22%+0.00% QoQ
- FII holding
- 6.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jubilant Ingrevia Ltd
All →Jubilant Ingrevia Earnings Call Transcript: Key Takeaways
Strong Q2 performance driven by volume growth across specialty chemicals and nutrition despite price softness in China.
Jubilant Ingrevia Management Change
Jubilant Ingrevia's Sr. Vice President & Head HR, Ms. Vinita Koul, resigned effective November 6, 2026. The departure is to pursue other interests.
Jubilant Ingrevia Employee Stock Options
Jubilant Ingrevia board approved grant of 3,037 RSUs to eligible employees under its 2021 ESOP scheme. Vesting occurs at end of third year from grant date.
Jubilant Ingrevia Q2 FY27 Results: Net Profit ₹111.4 Cr, Up 60.3% YoY
Jubilant Ingrevia Ltd reported revenue from operations of ₹1,394 Cr (+24.4% YoY) and net profit of ₹111.4 Cr (+60.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹111.4 Cr · +60.3% YoY
Jubilant Ingrevia Other Announcement
This is the quarterly shareholding pattern filing for Jubilant Ingrevia Ltd for the period ending September 30, 2026. It is a routine regulatory submission.
Jubilant Ingrevia Board Meeting Date
Jubilant Ingrevia Limited has scheduled a board meeting for October 27, 2026, to consider the unaudited standalone and consolidated financial results for the quarter.